

Practitioner's Docket No. ANGES-5

CHAPTER II

TRANSMITTAL LETTER  
TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/JP02/03239	29 March 2002 (29.03.02)	29 March 2002(29.03.02)
International Application Number	International Filing Date	International Earliest Priority Date

TITLE OF INVENTION: **DECOY COMPOSITIONS FOR TREATING AND PREVENTING  
BRAIN DISEASES AND DISORDERS**

APPLICANT(S): Yoshiki Sawa et al.

Mailstop PCT  
Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

- I. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. § 371:
  - a. This express request to immediately begin national examination procedures (35 U.S.C. § 371(f)).

---

**CERTIFICATION UNDER 37 C.F.R. 1.10\***  
(Express Mail label number is **mandatory**.)  
(Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date September 29, 2004 in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EV133111259US, addressed to the: Mail Stop PCT, Hon. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Claire J. Saintil-van Goodman

(type or print name of person mailing paper)

  
Signature of person mailing paper

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)—page 1 of 4)

b. The U.S. National Fee (35 U.S.C. § 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2. Fees amounts have been calculated based on the number of claims remaining following entry of the Preliminary Amendment and as shown below:

CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS	20 - 20 =	0	x \$9.00 =	\$0.00
	INDEPENDENT CLAIMS	4 - 3 =	1	x \$43.00 =	\$43.00
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$140.00				\$0.00
BASIC FEE	U.S. PTO WAS NOT INTERNATIONAL PRELIMINARY EXAMINATION AUTHORITY Where no international preliminary examination fee as set forth in § 1.482 has been paid to the U.S. PTO, and payment of an international search fee as set forth in § 1.445(a)(2) to the U.S. PTO: where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 C.F.R. § 1.492(a)(5)) ..... \$920.00				\$920.00
					= \$963.00
SMALL ENTITY	Reduction by ½ for filing by small entity, if applicable.				- \$481.50
TOTAL					\$481.50

A check in the amount of \$481.50 to cover the above fees is enclosed.

3. Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. § 371(c)(3)) have not been transmitted. Applicant chooses not to make amendments under PCT Article 19.
4. A translation of the amendments to the claims under PCT Article 19 (38 U.S.C. § 371(c)(3)) has not been transmitted for reasons indicated in section 3 above.
5. An unexecuted combination Declaration and Power of Attorney of the inventors (35 U.S.C. § 371(c)(4)) complying with 35 U.S.C. § 115 is submitted herewith, and such combination Declaration and Power of Attorney is attached to the application.
6. Print EFS Data Sheet.

**II. Other document(s) or information included:**

1. Additional documents:
  - a. A copy of PCT Application PCT/JP02/03239 including Specification (64 pages including Claims and Abstract); Drawings (4 sheets);
  - b. A copy of an English translation of the PCT Application PCT/JP02/03239;
  - c. Formal Drawings (4 pages);
  - d. Information Disclosure Statement;
  - e. PTO-1449 Form (with 5 cited references);
  - f. Paper copy of Sequence Listing (3 pages);
  - g. Statement Under 37 C.F.R. §§1.821-1.825;
  - h. CRF copy of Sequence Listing; and
  - i. Copy of PCT Publication No. WO 03/082331 A1 in Japanese.
2. The above items are being transmitted before 30 months from any claimed priority date.


**AUTHORIZATION TO CHARGE ADDITIONAL FEES**

The Director is hereby authorized to charge any additional fees, or to credit any overpayments, that may be required by this paper and during the entire pendency of this application to Account No. 06-1075.

Date: September 29, 2004

Reg. No. 27,794

Tel. No.: (212) 596-9000

  
**SIGNATURE OF PRACTITIONER**  
James F. Haley, Jr.  
Fish & Neave  
1251 Avenue of the Americas  
New York, NY 10020-1104  
Customer No. 1473

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group : Not Yet Assigned  
Applicants : Yoshiki Sawa et al.  
Application No. : Not Yet Assigned  
Confirmation No. : Not Yet Assigned  
Filed : Concurrently Herewith  
For : DECOY COMPOSITIONS FOR TREATING AND  
PREVENTING BRAIN DISEASES AND DISORDERS

New York, New York  
September 29, 2004


**Mailstop PCT**  
Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. §§1.821-1.825

Sir:

In accordance with 37 C.F.R. §§1.821-1.825, I hereby state that the paper copy of the Sequence Listing, submitted herewith, and the Computer Readable Form copy of the Sequence Listing, submitted herewith, are the same.

Respectfully submitted,

  
James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

c/o FISH & NEAVE (Customer No. 1473)  
1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090